CN111053777A - Ibutinib pharmaceutical composition and application thereof - Google Patents
Ibutinib pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN111053777A CN111053777A CN201811200402.0A CN201811200402A CN111053777A CN 111053777 A CN111053777 A CN 111053777A CN 201811200402 A CN201811200402 A CN 201811200402A CN 111053777 A CN111053777 A CN 111053777A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- paclitaxel
- ibrutinib
- pharmaceutically acceptable
- mol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 62
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 60
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 60
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims abstract description 53
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims abstract description 51
- 229960001507 ibrutinib Drugs 0.000 claims abstract description 51
- 239000003826 tablet Substances 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- HSVDYEDYDOKETI-UHFFFAOYSA-N 1,2-dihydroxy-2-(hydroxymethyl)octadecan-3-one Chemical compound CCCCCCCCCCCCCCCC(=O)C(O)(CO)CO HSVDYEDYDOKETI-UHFFFAOYSA-N 0.000 claims description 2
- RPULECGSRAAKJH-UHFFFAOYSA-M CCCCCCCCCCCCCCCCCC(=O)O[Ca] Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Ca] RPULECGSRAAKJH-UHFFFAOYSA-M 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- BBJQPKLGPMQWBU-UHFFFAOYSA-N Palmitinsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCC)C2 BBJQPKLGPMQWBU-UHFFFAOYSA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- BBJQPKLGPMQWBU-JADYGXMDSA-N cholesteryl palmitate Chemical group C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC)C1 BBJQPKLGPMQWBU-JADYGXMDSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- -1 oral preparations Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 11
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 abstract description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract description 2
- 235000008777 kaempferol Nutrition 0.000 abstract description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 230000006907 apoptotic process Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 208000037841 lung tumor Diseases 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229940124291 BTK inhibitor Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001946 anti-microtubular Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000637 radiosensitizating effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- ILWVKYVRVNWXHL-UHFFFAOYSA-M sodium;2-hydroxypropanoate;octadecanoic acid Chemical compound [Na+].CC(O)C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O ILWVKYVRVNWXHL-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- XAPNKXIRQFHCHN-QGOAFFKASA-N violacein Chemical compound O=C\1NC2=CC=CC=C2C/1=C(C(=O)N1)/C=C1C1=CNC2=CC=C(O)C=C21 XAPNKXIRQFHCHN-QGOAFFKASA-N 0.000 description 1
- LEJQUNAZZRYZKJ-UHFFFAOYSA-N violacein Natural products Oc1ccc2NCC(C3=CC(=C4/C(=O)Nc5ccccc45)C(=O)N3)c2c1 LEJQUNAZZRYZKJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition which is characterized by taking ibrutinib and paclitaxel or pharmaceutically acceptable derivatives thereof as effective components, wherein the mass ratio of the ibrutinib to the kaempferol or the pharmaceutically acceptable derivatives thereof is 1.5: 1-5: 1. The pharmaceutical composition has the advantages of improving the tumor inhibition effect and simultaneously showing a remarkable synergistic effect when the two are used in combination.
Description
Technical Field
The invention belongs to the field of medical application, and particularly relates to a pharmaceutical composition of ibrutinib and application thereof.
Background
Ibrutinib, also known as ibrutinib, known under the english name ibrutinib, tradename Imbruvica, chemically known as 1- [ (3R) -3- [ 4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-D ] pyrimidin-1-yl ] -1-piperidinyl ] -2-propen-1-one, having the following structure:
ibutinib is a small-molecule BTK inhibitor, can be selectively and covalently combined with cysteine residue (Cys-481) on the active site of BTK, irreversibly inhibits the activity of BTK, further inhibits the activation of a BCR signal pathway, effectively prevents tumors from migrating from B cells to lymphoid tissues suitable for tumor growth, reduces the malignant proliferation of the B cells and induces the apoptosis of the cells, thereby playing a role in treating CLL and MCL. Non-clinical studies have shown that ibrutinib is able to inhibit the proliferation and survival of malignant B lymphocytes in vivo. Has good curative effect on mantle cell lymphoma, chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma.
Paclitaxel, alias taxol, violacein, tertin, chemical name 5 β, 20-epoxy-1, 2 α,4, 7 β, 10 β, 13 α -hexahydroxy-taxane-11-en-9-one-4, 10-diacetate-2-benzoate-13 [ (2'R, 3' S) -N-benzoyl-3-phenylisoserine ester]Molecular weight 853.92, formula C47H51NO14. It is a novel anti-microtubule drug, which inhibits depolymerization by promoting tubulin polymerization, maintains tubulin stability, and inhibits cell mitosis. In vitro experiments demonstrated that paclitaxel had significant radiosensitizing effects, probably stopping the cells in the G2 and M phases that were sensitive to radiotherapy. Through the clinical research of II-III, the taxol is mainly suitable for ovarian cancer and breast cancer, and has certain curative effect on lung cancer, colorectal cancer, melanoma, head and neck cancer, lymphoma and cerebroma. At present, no report about synergistic effect of the combined drugs of ibrutinib and paclitaxel when used in combination in the aspect of tumor resistance is found.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide a pharmaceutical composition of ibrutinib and application thereof, wherein the pharmaceutical composition has a remarkable synergistic effect especially on the treatment of non-small cell lung cancer.
In order to achieve the purpose, the invention adopts the following technical scheme:
a pharmaceutical composition takes ibrutinib and paclitaxel or pharmaceutically acceptable derivatives thereof as effective components, wherein the mass ratio of the ibrutinib to the paclitaxel or pharmaceutically acceptable derivatives thereof is 1.5: 1-5: 1.
Preferably, the mass ratio of ibrutinib to paclitaxel or pharmaceutically acceptable derivatives thereof is 2: 1-5: 1.
Further preferably, the mass ratio of ibrutinib to paclitaxel or pharmaceutically acceptable derivatives thereof in the pharmaceutical composition is 3: 1-4: 1.
The pharmaceutically acceptable derivatives of paclitaxel in the pharmaceutical composition are docetaxel, paclitaxel, esmolol and dopamil.
The pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
The composition can be prepared into soft capsules, oral agents, injections, tablets and granules.
The composition can be prepared into tablets; the tablet is a double-layer tablet consisting of a tablet core and a quick release layer wrapping the tablet core, wherein the tablet core is a microcapsule prepared from paclitaxel or derivatives thereof and an excipient; the quick release layer is prepared from ibrutinib and auxiliary materials.
The excipient is cholesterol palmitate, propylene glycol and sodium stearate lactate; the auxiliary materials are selected from calcium monostearate, maltodextrin, monopalmitoyl glycerol and superfine silica gel powder.
The application of the pharmaceutical composition in the aspect of resisting tumor cells, in particular to the aspect of resisting non-small cell lung cancer.
Compared with the prior art, the invention has the following advantages: the paclitaxel and the ibrutinib are used together, so that the drug resistance of the ibrutinib is delayed, the toxic and side effects of the ibrutinib are reduced, and the drug effect of the ibrutinib is enhanced.
Detailed Description
The invention is further illustrated with reference to specific examples, without however being limited thereto.
Example 1
Determination of the concentration of ibrutinib in combination with paclitaxel and IC50 assay: this example uses the MTT method to analyze the drug sensitivity of a549 cells to ibrutinib and paclitaxel. A549 cells at 1 × 104The concentration of each mL is inoculated in a 96-well culture plate, 100 mu L of each well is added, and after overnight culture, drugs or control solution with different concentrations (20 mu L of each well) are added, wherein the ibutinib is provided with 8 concentration gradients which are respectively 10, 5, 2.5, 1.25, 0.625, 0.3125, 0.1500 and 0.0750 (the unit is mu mol/L); paclitaxel has 7 concentration gradients of 10, 5, 2.5,1.25, 0.625, 0.3125 and 0.1500 (units are all. mu. mol/L). Each drug concentration was set with 3 replicate wells, and the experiment was repeated 3 times with a drug-free control. And after 24h, 48h and 72h of culture, respectively adding 20 mu L of MTT solution into each hole, continuously culturing for 4h, respectively adding 130 mu L of dimethyl sulfoxide (DMSO) into each hole, fully and uniformly mixing on a vibrator, measuring an OD value at 490nm under a microplate reader, and calculating the concentration (IC50) of each drug required by 50% cell growth inhibition, thereby determining the concentration of the drug for the next step of experiment. The results are shown in table 1, and the inhibition effect of the two drugs on a549 cells is shown to be drug concentration and time-dependent. As can be seen from the results, the IC50 value of ibutinib on A549 cells is 2.38 +/-0.64 mu mol/L and the IC50 value of paclitaxel on A549 cells is 3.42 +/-0.46 mu mol/L after the cells are cultured for 72 hours.
TABLE 1 IC50 values (units: μmol/L, mean (x). + -. s) for A549 cells at various times
| Time (h) | Ibutinib (mu mol/L) | Taxol (mu mol/L) |
| 24 | 7.36±0.45 | 8.92±0.86 |
| 48 | 2.78±0.96 | 4.85±0.26 |
| 72 | 2.38±0.64 | 3.42±0.46 |
Example 2
Experiment of inhibition rate of ibutinib and paclitaxel pharmaceutical composition on A549 cell proliferation includes that logarithmic phase A549 cells are treated by 1 × 104The density per well was plated in 96-well plates at 50. mu.L/well and after 24h of incubation the drug was added (50. mu.L of either gazetinib, paclitaxel, combination or control per well). Wherein the concentration of the ibrutinib is respectively 0.01, 0.05, 0.1, 0.2, 0.4, 0.8 and 1.0 (the unit is mu mol/L), the concentration of the paclitaxel is respectively 0.01, 0.1 and 0.2, 0.4, 0.8, 1.6 and 2.0 (units are all μmol/L), the combined group concentrations are (0.01 μmol/L ibrutinib +0.01 μmol/L paclitaxel), (0.05 μmol/L ibrutinib +0.1 μmol/L paclitaxel), (0.1 μmol/L ibrutinib +0.2 μmol/L paclitaxel), (0.2 μmol/L ibrutinib +0.4 μmol/L paclitaxel), (0.4 μmol/L ibrutinib +0.8 μmol 1/L paclitaxel), (0.8 μmol/L ibrutinib +1.6 μmol/L paclitaxel) and (1.0 μmol/L ibrutinib +2.0 μmol/L paclitaxel), and each concentration is 4 replicates. Adding the drug, culturing for 72h, adding MTT 10 μ L with concentration of 5mg/L into each well, continuing culturing for 4h, adding DMSO80 μ L, shaking for 10min, measuring OD value of each well with enzyme labeling instrument (wavelength 490nm), and calculating cell proliferation inhibition rate according to the following formula:
judging the characteristic of the combination of the paclitaxel and the ibrutinib by using the q value, and calculating the formula:
wherein EA and EB are the single-use inhibition rates of paclitaxel and ibrutinib respectively, and EAB is the combined inhibition rate of the two medicines. When q is more than 1.15, the synergistic effect is obtained, q is more than or equal to 0.85 and less than or equal to 1.15, the additive effect is obtained, and q is less than 0.85, the antagonistic effect is obtained.
The research result shows that: after the A549 cells are treated by combination of paclitaxel and ibrutinib, the cell growth inhibition effect appears at 72h, and the cell inhibition rate is obviously increased compared with that of the paclitaxel or the ibrutinib which is singly used. The paclitaxel group has an inhibition rate of 10-25%, the ibrutinib group has an inhibition rate of 20-30%, and the combined group has an inhibition rate of 30-60%. Meanwhile, the q value of 2 mu mol/L paclitaxel and 1 mu mol/L ibutinib in 72h is 1.26, which shows a synergistic effect, and the q values of the other groups are 0.86-1.05, which shows an additive effect. In addition, the inhibition rate of the combination group increases with the increase of the drug concentration.
Example 3
In vitro inhibition experiments on various tumor cells with single drugs and combined drugs: the inhibition of the proliferation of lung tumor cells A549 and liver cancer cells HepG2 by ibutinib (1.5. mu. mol/L), paclitaxel (3.0. mu. mol/L) alone and two (0.5. mu. mol/L of ibutinib +1. mu. mol/L of paclitaxel) in combination were determined by the MTT method within 72 hours. The test results are shown in table 2, compared with the single drug, the combined drug (1.0 mu mol/L of ibutinib and 2.0 mu mol/L of paclitaxel) has better inhibition effect on lung tumor cells and liver cancer cells, and especially has better inhibition effect on lung tumor cells A549.
TABLE 2 inhibition of cancer cell proliferation by paclitaxel, ibrutinib and combinations thereof
By using
| Pharmaceutical composition | HepG2 | A549 |
| Control group 5-Fu (2. mu. mol/L, 100. mu.L) | 86.2％ | 81.3％ |
| Ibutotinib (1.5. mu. mol/L, 100. mu.L) | 46.8％ | 52.4％ |
| Taxol (3.0. mu. mol/L, 100. mu.L) | 42.3％ | 49.8％ |
| 1.0. mu. mol/L Ibutinib + 2.0. mu. mol/L paclitaxel (total 100. mu.L) | 91.4％ | 95.6％ |
Example 4
Experiment on the effect of the combined use of the pharmaceutical composition on apoptosis of A549 lung tumor cells: flow cytometry is adopted to analyze the influence of the individual use and the combined use of the ibrutinib and the paclitaxel on the apoptosis of A549 cells. A549 cells at 1 × 104The cells were inoculated in a 96-well plate at a concentration of 100. mu.L/well and cultured
Adding the medicine after night, (each well contains 100 mu L of ibrutinib, paclitaxel, combination or control liquid) ibrutinib is provided with 7 concentration gradients which are respectively 0.01, 0.05, 0.1, 0.2, 0.4, 0.8 and 1.0 (the unit is mu mol/L); paclitaxel is provided with 7 concentration gradients of 0.01, 0.1, 0.2, 0.4, 0.8, 1.6 and 2.0 (unit is mu mol/L); the concentrations of the combination group (ibrutinib + paclitaxel) were (0.01. mu. mol/L ibrutinib + 0.01. mu. mol/L kaempferol), (0.05. mu. mol/L ibrutinib + 0.1. mu. mol/L paclitaxel), (0.1. mu. mol/L ibrutinib + 0.2. mu. mol/L paclitaxel), (0.2. mu. mol/L ibrutinib + 0.4. mu. mol/L paclitaxel), (0.4. mu. mol/L ibrutinib + 0.8. mu. mol/L paclitaxel), (0.8. mu. mol/L ibrutinib + 1.6. mu. mol/L paclitaxel) and (1.0. mu. mol/L ibrutinib + 2.0. mu. mol/L paclitaxel), respectively. 3 repeated wells are set for each drug concentration, the experiment is repeated 3 times, a control group without the drug is set, and the apoptosis rate is measured after 72 hours.
The results of the study on the effect of ibutinib and paclitaxel on A549 cell apoptosis show that: when the ibutinib (the concentration is 1.5 mu mol/L) or the paclitaxel (the concentration is 3.0 mu mol/L) acts alone, the apoptosis rate is increased compared with that of a control group. Among them, the control group had an apoptosis rate of 3.6%, ibrutinib had an apoptosis rate of 15.3%, and paclitaxel had an apoptosis rate of 11.8%. The apoptosis rate of the combined medicine group (1.0 mu mol/L ibutinib +2.0 mu mol/L paclitaxel) is obviously increased to 60.5 percent, and compared with the single administration, the combined medicine group has obvious synergistic effect.
Claims (9)
1. The pharmaceutical composition is characterized by taking ibrutinib and paclitaxel or pharmaceutically acceptable derivatives thereof as effective components, wherein the mass ratio of ibrutinib to paclitaxel or pharmaceutically acceptable derivatives thereof is 1.5: 1-5: 1.
2. The pharmaceutical composition according to claim 1, wherein the mass ratio of ibrutinib to paclitaxel or pharmaceutically acceptable derivatives thereof is 2: 1-5: 1.
3. The pharmaceutical composition according to claim 1, wherein the mass ratio of ibrutinib to paclitaxel or pharmaceutically acceptable derivatives thereof in the pharmaceutical composition is 3: 1-4: 1.
4. The pharmaceutical composition of any one of claims 1-3, wherein the pharmaceutically acceptable derivative of paclitaxel in the pharmaceutical composition is docetaxel, paclitaxel, esbiotine, and dophenanthrene.
5. The pharmaceutical composition of any one of claims 1-3, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
6. The pharmaceutical composition according to any one of claims 1 to 3, wherein the composition is formulated as soft capsules, oral preparations, injections, tablets, granules.
7. The pharmaceutical composition of claim 6, wherein the composition is formulated as a tablet; the tablet is a double-layer tablet consisting of a tablet core and a quick release layer wrapping the tablet core, wherein the tablet core is a microcapsule prepared from paclitaxel or derivatives thereof and an excipient; the quick release layer is prepared from ibrutinib and auxiliary materials.
8. The pharmaceutical composition of claim 7, wherein the excipient is cholesterol palmitate, propylene glycol, sodium stearate; the auxiliary materials are selected from calcium monostearate, maltodextrin, monopalmitoyl glycerol and superfine silica gel powder.
9. Use of a pharmaceutical composition according to any one of claims 1 to 3 for combating tumour cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811200402.0A CN111053777A (en) | 2018-10-16 | 2018-10-16 | Ibutinib pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811200402.0A CN111053777A (en) | 2018-10-16 | 2018-10-16 | Ibutinib pharmaceutical composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111053777A true CN111053777A (en) | 2020-04-24 |
Family
ID=70296367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811200402.0A Withdrawn CN111053777A (en) | 2018-10-16 | 2018-10-16 | Ibutinib pharmaceutical composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111053777A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160022684A1 (en) * | 2014-07-25 | 2016-01-28 | Pharmacyclics Llc | Bet inhibitor and bruton's tyrosine kinase inhibitor combinations |
| CN106714909A (en) * | 2014-08-08 | 2017-05-24 | 药品循环有限责任公司 | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| CN106999495A (en) * | 2014-11-17 | 2017-08-01 | 药品循环有限责任公司 | TLR inhibitor and the combination of bruton's tyrosine kinase inhibitor |
| US20180071294A1 (en) * | 2013-08-12 | 2018-03-15 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
| CN108024996A (en) * | 2015-07-31 | 2018-05-11 | 药品循环有限责任公司 | Combinations of Bruton's tyrosine kinase inhibitors and uses thereof |
-
2018
- 2018-10-16 CN CN201811200402.0A patent/CN111053777A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180071294A1 (en) * | 2013-08-12 | 2018-03-15 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
| US20160022684A1 (en) * | 2014-07-25 | 2016-01-28 | Pharmacyclics Llc | Bet inhibitor and bruton's tyrosine kinase inhibitor combinations |
| CN106714909A (en) * | 2014-08-08 | 2017-05-24 | 药品循环有限责任公司 | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| CN106999495A (en) * | 2014-11-17 | 2017-08-01 | 药品循环有限责任公司 | TLR inhibitor and the combination of bruton's tyrosine kinase inhibitor |
| CN108024996A (en) * | 2015-07-31 | 2018-05-11 | 药品循环有限责任公司 | Combinations of Bruton's tyrosine kinase inhibitors and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| DANIEL MASSÓ-VALLÉS: "Ibrutinib repurposing: from B-cell malignancies to solid tumors", 《ONCOSCIENCE》 * |
| 王业东: "激酶类抑制剂对紫杉醇羟化途径的选择性抑制以及药物相互作用研究", 《中国优秀硕士学位论文全文数据库（电子期刊）》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12178792B2 (en) | Pharmaceutical composition and use thereof in preparing drug for treating tumor multi-drug resistance | |
| EP3053578B1 (en) | Combination cancer therapy using azabicyclo compound | |
| CN106822905A (en) | The medicine and purposes of inhibitor containing Survivin and IRE1 inhibitor | |
| El‐Far et al. | Cancer metabolism control by natural products: Pyruvate kinase M2 targeting therapeutics | |
| WO2022188491A1 (en) | Tumor chemotherapy pharmaceutical composition | |
| Xiaokaiti et al. | Natural product regulates autophagy in cancer | |
| Huang et al. | Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures | |
| AU2017214157A1 (en) | Application of phosphodiesterase 4 inhibitor ZL-n-91 in preparation of medications for lung cancer proliferation and metastasis | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| CN111053777A (en) | Ibutinib pharmaceutical composition and application thereof | |
| Limbach et al. | Baicalein activates 5’adenosine monophosphate-activated protein kinase, inhibits the mammalian target of rapamycin, and exhibits antiproliferative effects in pancreatic neuroendocrine tumors in vitro and in vivo | |
| CN112089710A (en) | Application of 4-hydroxyisoleucine in preparation of antitumor drugs | |
| CN113786491B (en) | An anti-tumor combined preparation containing tetrandrine, dihydroquercetin or quercetin | |
| WO2007073646A1 (en) | The application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation, chemotherapy sensitization | |
| CN111821303A (en) | Application of vortioxetine and its salts in the preparation of antitumor drugs | |
| CN101428034B (en) | Antineoplastic combined medicament with enhancing and poison-reducing character | |
| Cortes et al. | Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies | |
| CN110693903B (en) | Medicine for treating acute monocytic leukemia and application of arsenic trioxide and dihydroartemisinin | |
| CN113274394A (en) | Pharmaceutical composition for treating tyrosine kinase inhibitor drug-resistant non-small cell lung cancer | |
| CN110141664B (en) | Pharmaceutical composition for treating acute myeloid leukemia | |
| CN101380325A (en) | Composition of artemisinin derivatives and vinorelbine and application thereof | |
| CN107412736B (en) | Anti-tumor combined medicine and application thereof in preparing anti-cancer medicine | |
| CN115089576B (en) | Application of the combination of luteolin and chicoric acid in the preparation of breast cancer treatment drugs | |
| CN111110678A (en) | Pharmaceutical composition containing crizotinib and kaempferol and application thereof | |
| Li et al. | The ZuoJinWan formula inhibits glycolysis of cisplatin resistant gastric cancer cells via p53 acetylation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200424 |